August 24, 2015
The European Medicines Agency (EMA) has accepted Takeda Pharmaceutical’s marketing authorization application (MAA) for its novel once-weekly oral proteasome inhibitor ixazomib, seen as a successor to Velcade (bortezomib), for the treatment of multiple myeloma, the company said on August 21...read more